Evidence map›Paper›PMID 35805713›Full record

ArticleInternational journal of environmental research and public health2022

Detection of COVID-19 Patients Using Machine Learning Techniques: A Nationwide Chilean Study.

Pablo Ormeño, Gastón Márquez, Camilo Guerrero-Nancuante, Carla Taramasco

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pablo OrmeñoEscuela de Ingenieria y Negocios, Universidad de Viña del Mar, Viña del Mar 2520000, Chile.ORCID 0000-0001-5591-3518
Gastón MárquezDepartamento de Electrónica e Informática, Universidad Técnica Federico Santa María, Millennium Nucleus on Sociomedicine, Concepción 4030000, Chile.ORCID 0000-0003-0167-5969
Camilo Guerrero-NancuanteEscuela de Enfermería, Universidad de Valparaíso, Valparaíso 2500000, Chile.ORCID 0000-0001-6527-6292
Carla TaramascoFacultad de Ingeniería, Universidad Andrés Bello, Millennium Nucleus on Sociomedicine, Viña del Mar 2520000, Chile.ORCID 0000-0001-8318-4201

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epivigila is a Chilean integrated epidemiological surveillance system with more than 17,000,000 Chilean patient records, making it an essential and unique source of information for the quantitative and qualitative analysis of the COVID-19 pandemic in Chile. Nevertheless, given the extensive volume of data controlled by Epivigila, it is difficult for health professionals to classify vast volumes of data to determine which symptoms and comorbidities are related to infected patients. This paper aims to compare machine learning techniques (such as support-vector machine, decision tree and random forest techniques) to determine whether a patient has COVID-19 or not based on the symptoms and comorbidities reported by Epivigila. From the group of patients with COVID-19, we selected a sample of 10% confirmed patients to execute and evaluate the techniques. We used precision, recall, accuracy, F1-score, and AUC to compare the techniques. The results suggest that the support-vector machine performs better than decision tree and random forest regarding the recall, accuracy, F1-score, and AUC. Machine learning techniques help process and classify large volumes of data more efficiently and effectively, speeding up healthcare decision making.

Indexed as

COVID-19ChileHumansMachine LearningPandemicsSupport Vector MachinecomorbiditiesEpivigilamachine learningsymptoms

Identifiers

PMID35805713
PMCPMC9265284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.